valproic acid has been researched along with Brain Damage, Chronic in 10 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Brain Damage, Chronic: A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A minimum of one steady state trough blood sample and one dosage interval urine were collected during days 3-6 and during days 7-14 post-injury." | 2.69 | Increases in metabolism of valproate and excretion of 6beta-hydroxycortisol in patients with traumatic brain injury. ( Adams, CA; Anderson, GD; Awan, AB; Temkin, NR; Winn, HR, 1998) |
| " Here we determined whether chronic administration of common AEDs during early life alters cell proliferation and neurogenesis in the hippocampus." | 1.35 | Long-term antiepileptic drug administration during early life inhibits hippocampal neurogenesis in the developing brain. ( Cai, F; Cao, J; Chen, J; Li, S; Zhang, X, 2009) |
| "Treatment with haloperidol in all patients and with dipropylacetic acid in three patients did not appear to modify the CSF, HVA, and 5HIAA concentrations, the plasma DBH activity, or the DA uptake." | 1.26 | Biochemical aspects of Huntington's chorea. ( Algeri, S; Branciforti, A; Calderini, G; Caraceni, T; Consolazione, A; Dall'olio, A; Girotti, F; Morselli, PL; Riva, E; Spreafico, R, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J | 1 |
| Cai, F | 1 |
| Cao, J | 1 |
| Zhang, X | 1 |
| Li, S | 1 |
| Rousseau, MC | 1 |
| Montana, M | 1 |
| Villano, P | 1 |
| Catala, A | 1 |
| Blaya, J | 1 |
| Valkov, M | 1 |
| Allouard, Y | 1 |
| Bugni, E | 1 |
| Williams, JA | 1 |
| Barreiro, CJ | 1 |
| Nwakanma, LU | 1 |
| Lange, MS | 1 |
| Kratz, LE | 1 |
| Blue, ME | 1 |
| Berrong, J | 1 |
| Patel, ND | 1 |
| Gott, VL | 1 |
| Troncoso, JC | 1 |
| Johnston, MV | 1 |
| Baumgartner, WA | 1 |
| Chayasirisobhon, S | 1 |
| Russell, M | 1 |
| Stoll, AL | 1 |
| Banov, M | 1 |
| Kolbrener, M | 1 |
| Mayer, PV | 1 |
| Tohen, M | 1 |
| Strakowski, SM | 1 |
| Castillo, J | 1 |
| Suppes, T | 1 |
| Cohen, BM | 1 |
| Helmstaedter, C | 1 |
| Wagner, G | 1 |
| Elger, CE | 1 |
| Wroblewski, BA | 1 |
| Joseph, AB | 1 |
| Kupfer, J | 1 |
| Kalliel, K | 1 |
| Anderson, GD | 1 |
| Awan, AB | 1 |
| Adams, CA | 1 |
| Temkin, NR | 1 |
| Winn, HR | 1 |
| Caraceni, T | 1 |
| Calderini, G | 1 |
| Consolazione, A | 1 |
| Riva, E | 1 |
| Algeri, S | 1 |
| Girotti, F | 1 |
| Spreafico, R | 1 |
| Branciforti, A | 1 |
| Dall'olio, A | 1 |
| Morselli, PL | 1 |
| Wiedemann, G | 1 |
| Haupt, M | 1 |
| Rommel, A | 1 |
| Rommel, KF | 1 |
| Biesenbach, R | 1 |
| Schmidt, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression: A 42-Day, Single-Site, Forced-Titration, Parallel Group, Randomized, Double-Blind, Placebo Controlled Trial[NCT00621751] | 70 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Study physician's impression of change since study onset. Clinicians Global Impressions of Change (CGI) is a sensitive, standardized tool to assess psychopharmacologic treatment response completed by the study physician. The Global Improvement (GI) CGI subscale documented the clinician's impression of change. The GI uses a 7-point scale to assess beneficial and negative effects. Low GI values (1 -3) indicate improvement; higher values (4-7) represent worsening. (NCT00621751)
Timeframe: 42 days
| Intervention | units on a scale (Mean) |
|---|---|
| Carbamazepine | 3.1 |
| Placebo | 2.9 |
Global Impression of Change (GIC) is a 5-item Likert Scale rated participants and observer impression of change in the person with TBI. Responses range 1 = much improved to 5 = much worse. (NCT00621751)
Timeframe: 42 days
| Intervention | units on a scale (Mean) |
|---|---|
| Carbamazepine | 3.3 |
| Placebo | 3.1 |
Global Impression of Change (GIC) is a 5-item Likert Scale rated participants and observer impression of change in the person with TBI. Responses range 1 = much improved to 5 = much worse. (NCT00621751)
Timeframe: Day-42
| Intervention | score on a scale (Mean) |
|---|---|
| Carbamazepine | 3.1 |
| Placebo | 3.1 |
Neuropsychiatry Inventory-Irritability (NPI-I) & Aggression domains (NPI-A): NPI is a 40-item assessment of 12 behavioral domains (NPI-I & NPI-A domains used in this study). The most problematic aspect of each domain is graded for severity (1=mild, to 3=severe) and frequency (1-4 with 4 representing highest frequency); the domain scores (0-12) are the product of severity and frequency. To best reflect treatment target intent and meet parametric statistical method criteria, the primary outcome was a composite measure of observer-rated NPI-I & -A domains transformed to a Rasch logit scale running from 0 (best) to 100 (worse) units (i.e., observer-rated NPI-I/A Rasch construct scores). Mean day-42 observer-rated NPI-I/A Rasch construct scores were compared between placebo vs. carbamazepine using ANCOVA with baseline score as covariate. (NCT00621751)
Timeframe: 42 days
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Carbamazepine | 37.7 |
| Placebo | 36.7 |
Neuropsychiatry Inventory-Irritability (NPI-I) & Aggression domains (NPI-A): NPI is a 40-item assessment of 12 behavioral domains (NPI-I & NPI-A domains used in this study). The most problematic aspect of each domain is graded for severity (1=mild, to 3=severe) and frequency (1-4 with 4 representing highest frequency); the domain scores (0-12) are the product of severity and frequency. To best reflect treatment target intent and meet parametric statistical method criteria, a composite measure of participant-rated NPI-I & -A domains transformed to a Rasch logit scale running from 0 (best) to 100 (worse) units (i.e., participant-rated NPI-I/A Rasch construct scores). Mean day-42 participant-rated NPI-I/A Rasch construct scores were compared between placebo vs. CBZ using ANCOVA with baseline score as covariate. (NCT00621751)
Timeframe: Day 42
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Carbamazepine | 37.5 |
| Placebo | 36.4 |
Proportion of participants with Minimal Clinically Important Difference (MCID) on Neuropsychiatric Inventory Irritability-Aggression Composite Measure completed by Observer. Specifically, the proportion of participants that experienced a decrease of > 1 (MCID) in the NPI-I/A Rasch construct score (i.e., participants that are considered to have meaningful reduction in irritability/aggression) from baseline to day-42 between the groups using a chi-square test. MCID was defined as 0.5 times the standard deviation of baseline scores. (NCT00621751)
Timeframe: 42-day
| Intervention | Participants (Count of Participants) |
|---|---|
| Carbamazepine | 20 |
| Placebo | 26 |
Proportion of participants with Minimal Clinically Important Difference (MCID) on Neuropsychiatric Inventory Irritability-Aggression Composite Measure completed by Participant. Specifically, the proportion of participants that experienced a decrease of > 1 (MCID) in the NPI-I/A Rasch construct score (i.e., participants that are considered to have meaningful reduction in irritability/aggression) from baseline to day-42 between the groups using a chi-square test. MCID was defined as 0.5 times the standard deviation of baseline scores. (NCT00621751)
Timeframe: Day-42
| Intervention | Participants (Count of Participants) |
|---|---|
| Carbamazepine | 21 |
| Placebo | 16 |
1 trial available for valproic acid and Brain Damage, Chronic
| Article | Year |
|---|---|
Increases in metabolism of valproate and excretion of 6beta-hydroxycortisol in patients with traumatic brain injury.
Topics: Adult; Aged; Anticonvulsants; Brain Damage, Chronic; Brain Injuries; Female; Humans; Hydrocortisone; | 1998 |
9 other studies available for valproic acid and Brain Damage, Chronic
| Article | Year |
|---|---|
Long-term antiepileptic drug administration during early life inhibits hippocampal neurogenesis in the developing brain.
Topics: Age Factors; Animals; Animals, Suckling; Anticonvulsants; Apoptosis; Brain Damage, Chronic; Carbamaz | 2009 |
Valproic acid-induced encephalopathy in very long course treated patients.
Topics: Adolescent; Adult; Anticonvulsants; Brain Damage, Chronic; Dose-Response Relationship, Drug; Female; | 2009 |
Valproic acid prevents brain injury in a canine model of hypothermic circulatory arrest: a promising new approach to neuroprotection during cardiac surgery.
Topics: Animals; Apoptosis; Aspartic Acid; Behavior, Animal; Biomarkers; Brain; Brain Chemistry; Brain Damag | 2006 |
Valproic acid and intractable seizures in severely brain-damaged patients.
Topics: Adolescent; Adult; Brain Damage, Chronic; Child; Epilepsy; Female; Humans; Male; Middle Aged; Valpro | 1983 |
Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders.
Topics: Bipolar Disorder; Brain Damage, Chronic; Cohort Studies; Double-Blind Method; Electroencephalography | 1994 |
Differential effects of first antiepileptic drug application on cognition in lesional and non-lesional patients with epilepsy.
Topics: Attention; Brain Damage, Chronic; Carbamazepine; Cognition Disorders; Electroencephalography; Epilep | 1993 |
Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired brain injury.
Topics: Activities of Daily Living; Adult; Aggression; Anticonvulsants; Brain Concussion; Brain Damage, Chro | 1997 |
Biochemical aspects of Huntington's chorea.
Topics: Adult; Age Factors; Blood Platelets; Brain Damage, Chronic; Dopamine; Dopamine beta-Hydroxylase; Fem | 1977 |
[Incidence of pathologic ammonia concentrations in the plasma in children with seizure disorders treated with Convulsofin/Convulex and other anticonvulsants in comparison with children with brain damage and healthy children].
Topics: Adolescent; Ammonia; Anticonvulsants; Brain Damage, Chronic; Chemical and Drug Induced Liver Injury; | 1990 |